4576

D.Western Therapeutics Institute, Inc.

株式会社デ・ウエスタン・セラピテクス研究所
Healthcare · Biotechnology
D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. It offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. The company is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; and DWR-2206, a regenerative medicine cell-product for bullous keratopathy. D. Western Therapeutics Institute, Inc. was founded in 1999 and is headquartered in Nagoya, Japan.
← Companies
Price
¥76
Market Cap
¥4.1B
Ent. Value
¥3.0B
Net Cash
¥1.1B
Shares Out.
54.3M
P / E
—
EV / EBIT
—
P / Book
2.87×
P / NCAV
3.21×
Div. Yield
—
Financials
Metric FY 2025
EDINET ↗ 		FY 2024
EDINET ↗ 		FY 2023
EDINET ↗ 		FY 2022
EDINET ↗ 		FY 2021
EDINET ↗
Net Sales ¥388M ¥472M ¥428M ¥448M ¥414M
Cost of Sales ¥39M ¥47M ¥37M ¥28M ¥20M
Gross Profit ¥349M ¥425M ¥392M ¥421M ¥394M
SG&A ¥969M ¥1.6B ¥1.2B ¥726M ¥566M
Operating Income ¥-620M ¥-1.2B ¥-799M ¥-306M ¥-172M
Non-Operating Income ¥10M ¥2M ¥7M ¥38M ¥18M
Interest Income ¥2M ¥0M ¥0M ¥0M ¥0M
Non-Operating Expenses ¥21M ¥21M ¥5M ¥28M ¥6M
Interest Expense ¥9M ¥5M ¥2M ¥3M ¥4M
Ordinary Income ¥-630M ¥-1.2B ¥-796M ¥-296M ¥-160M
Pre-tax Income ¥-630M ¥-1.3B ¥-827M ¥-440M ¥-160M
Income Taxes ¥2M ¥2M ¥2M ¥2M ¥2M
Current Tax ¥2M ¥2M ¥2M ¥2M ¥2M
Net Income (owners) ¥-632M ¥-1.3B ¥-812M ¥-430M ¥-149M
Minority Interest — — ¥-16M ¥-12M ¥-12M
Comprehensive Income ¥-632M ¥-1.3B ¥-828M ¥-442M ¥-161M
EBITDA ¥-572M ¥-1.2B ¥-750M ¥-260M ¥-126M
EPS ¥-13.19 ¥-36.74 ¥-25.56 ¥-14.50 ¥-5.08
Shares Outstanding 54.3M 41.6M 32.1M 30.9M 29.4M
Shares Issued (total) 54.3M 41.6M 32.1M 30.9M 29.4M
Treasury Shares 0.0M 0.0M 0.0M 0.0M 0.0M